Recent Analysts’ Ratings Updates for Tandem Diabetes Care (TNDM)

Tandem Diabetes Care (NASDAQ: TNDM) recently received a number of ratings updates from brokerages and research firms:

• 11/10/2025 – Tandem Diabetes Care had its price target raised by analysts at Barclays PLC from $51.00 to $55.00. They now have an “overweight” rating on the stock.
• 11/10/2025 – Tandem Diabetes Care had its price target raised by analysts at Morgan Stanley from $13.00 to $17.00. They now have an “equal weight” rating on the stock.
• 11/10/2025 – Tandem Diabetes Care had its “hold” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $17.00 price target on the stock, up previously from $16.00.
• 11/8/2025 – Tandem Diabetes Care was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/7/2025 – Tandem Diabetes Care had its price target raised by analysts at Wells Fargo & Company from $13.00 to $14.00. They now have an “equal weight” rating on the stock.
• 10/26/2025 – Tandem Diabetes Care was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/21/2025 – Tandem Diabetes Care is now covered by analysts at Stifel Nicolaus. They set a “hold” rating and a $15.00 price target on the stock.
• 10/18/2025 – Tandem Diabetes Care was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 10/15/2025 – Tandem Diabetes Care was given a new $16.00 price target on by analysts at Truist Financial Corporation. They now have a “hold” rating on the stock.
• 10/8/2025 – Tandem Diabetes Care had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Tandem Diabetes Care had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $15.00 price target on the stock, up previously from $11.00.
• 9/29/2025 – Tandem Diabetes Care had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $24.00 price target on the stock.
• 9/27/2025 – Tandem Diabetes Care had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.